Analyse Alto Neuroscience, Inc. (ANRO) — Kairos Score 62/100

À propos de Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Informations clés

🕴️ Activité des initiés (90 jours)

7 transactions — 0 achats et 3 ventes déclarés par les dirigeants de Alto Neuroscience, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur ANRO dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

14 articles récents sur ANRO.

• Alto Neuroscience Announces Participation in Upcoming Investor Conferences
• Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.